Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer

Urology
R S RosenbaumJ Fleischmann

Abstract

This investigation attempted to determine whether the degree of fibronectin expression in the bladders of patients with invasive transitional cell carcinoma correlated with their clinical response to intravesical bacille Calmette-Guerin (BCG) therapy. Following transurethral resection of all invasive disease, 13 patients with Stages T2-T4 bladder cancer were administered intravesical BCG (fo 6 weeks followed by monthly instillations). Fibronectin expression in the patients' resected tumors and normal mucosa was determined by immunohistochemical staining techniques. Minimum disease-free follow-up was 60 months. Only 1 of 13 patients had neither local nor systemic disease recurrence; 10 of 13 patients developed systemic disease and 7 patients died from metastases. Fibronectin expression was not correlated with the clinical response to BCG. Intravesical BCG therapy for the treatment of muscle invasive transitional cell carcinoma of the bladder is ineffective. Fibronectin expression in the bladder of patients with invasive disease is variable and does not correlate significantly with the clinical response to BCG therapy.

References

Jan 1, 1992·Journal of Cellular Biochemistry. Supplement·H W Herr
Sep 1, 1990·The Journal of Urology·R E WeissM J Droller
Feb 1, 1990·The Journal of Urology·H B GrossmanA Flint
Nov 1, 1986·The Journal of Cell Biology·P CastellaniL Zardi
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J P QuigleyL M Sullivan
Feb 1, 1988·The Journal of Urology·T L RatliffW J Catalona
Dec 1, 1987·British Journal of Urology·I G ConnC J Hilton
Oct 1, 1984·The Journal of Urology·N R Netto, G C Lemos

❮ Previous
Next ❯

Citations

Jan 1, 1997·World Journal of Urology·S Serels, J Fleischmann
Jun 27, 2002·Current Urology Reports·A M Kamat, D L Lamm
Feb 25, 2000·Urology·A M Kamat, D L Lamm
Sep 2, 1998·British Journal of Urology·N A Mungan, J A Witjes
Apr 2, 2013·The Urologic Clinics of North America·Jay B Shah, Ashish M Kamat
Jun 23, 2011·Expert Review of Vaccines·Michael A MorseBrant A Inman
Mar 3, 2017·Journal of Virology·Sebastien DelpeutChristopher D Richardson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.